Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while Vanguard S&P 500 Growth Index Fund ETF trades at $84.5 (market cap $27.10B). The key difference: Vanguard S&P 500 Growth Index Fund ETF is far larger — about 3.7× Spyre Therapeutics Inc. Common Stock's market cap, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard S&P 500 Growth Index Fund ETF for 56 Days on average.
| SYRE | VOOG | |
|---|---|---|
Market Cap | $7.35B | $27.10B |
Volume | 1,624,631 | 1,536,013 |
Sector | Health | Broad Market / Factor |
52-Week High | $108.92 | $87.81 |
52-Week Low | $22.18 | $65.32 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $6.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VOOG trades at $86.9, down slightly by 0.02% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, tracking S&P 500 growth stocks, has seen strong institutional buying and positive media coverage highlighting its long-term growth potential and low expense ratio of 0.07%.
The outlook remains favorable for growth-oriented investors, supported by historical outperformance and sector concentration in technology. Key risks include market volatility and reliance on mega-cap tech stocks, but analyst sentiment and institutional inflows suggest continued confidence in its strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
